GlassScriptPhysician profile
Luisito Torregosa
NPI 1790441590
$1,815.55
in general payments reported to CMS, 2019-2025
12 companies · $64.87 in 2025
The $64.87 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $402 · 2023: $801 · 2024: $547 · 2025: $64.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.90 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $240.77 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $234.75 | 2022-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $176.26 | 2022-2025 | Trintellix |
| Lundbeck LLC | $169.73 | 2022-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $120.86 | 2022-2023 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $120.12 | 2023-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $99.63 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $83.18 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $41.83 | 2022-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $39.94 | 2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $34.58 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisito Torregosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.